The IHR conducts research aimed at improving precision medicine approaches in care delivery to inform guidelines for best practices both locally at Kaiser Permanente Colorado and nationally. The use of precision medicine technologies to identify targeted treatment or care plans based on an individual patient's risk factors, genes, and disease characteristics is a critical area of medical research nationwide. IHR researchers are working to find novel approaches in precision medicine by evaluating biomarkers in cancer precursor lesions, improving data capture and tracking for tests related to precision medicine, and understanding how members and clinicians understand and use precision medicine information.
Precision Medicine Researchers
Andrea Burnett-Hartman, PhD, MPHInvestigator
Debra P. Ritzwoller, PhDSenior Investigator
Heather Spencer Feigelson, PhD, MPHSenior Investigator
Serrated Colorectal Cancer: An Emerging Disease SubtypeInvestigators: Andrea Burnett-Hartman, PhD, MPH
The objective of this project is to characterize factors relating to the genetic predisposition, clinical presentation, and prognosis of serrated colorectal cancer.
Funder:National Cancer Institute
Study End Date: 4/30/2021
Kaiser Permanente National Research BankInvestigators: Andrea Burnett-Hartman, PhD, MPH and Heather Spencer Feigelson, PhD, MPH
The KP National Biobank is a collaboration across all Kaiser regions funded by the Kaiser Foundation Health Plan. The goal of the biobank is to collect blood and/or tissue samples on 400,000 Kaiser Permanente members and utilize them, combined with survey data and medical information, to create a state-of-the-art resource for genetic and health services research.
Funder:Kaiser Foundation Health Plan
Study End Date: 12/31/2019
Clinical Sequencing Evidence-Generating Research (CSER2)Investigators: Heather Spencer Feigelson, PhD, MPH
The goal of this project is to investigate the implementation of exome sequencing in practice settings that primarily serve racially, ethnically, and socioeconomically diverse patients while examining the needs of both patients and clinicians. We will evaluate the clinical utility of exome sequencing in healthy adults of reproductive age at risk for hereditary cancer syndromes (Lynch Syndrome and Hereditary Breast and Ovarian Cancer). We will evaluate and tailor for diverse populations the critical interactions in the program, including the consent process, choices for reporting additional findings, and the response to results disclosure.
Funder:National Human Genome Research Institute
Study End Date: 5/31/2021
The Association Between Molecular Markers in Colorectal Sessile Serrated Polyps and Colorectal Cancer RiskInvestigators: Andrea Burnett-Hartman, PhD, MPH
This project proposes to identify biomarkers in sessile serrated polyps that are associated with an increased risk of colorectal cancer. These biomarkers may later be used to guide colorectal cancer surveillance recommendations or included in stool-based DNA panels to improve the effectiveness of stool-based colorectal cancer screening tests.
Funder:Department of Defense
Study End Date: 7/31/2018
Molecular Markers of Risk of Subsequent Breast Cancer in Women with Ductal Carcinoma in SituInvestigators: Heather Spencer Feigelson, PhD, MPH
The aim of this study is to identify miRNA expression changes associated with risk of invasive breast cancer among a cohort of women initially diagnosed with DCIS.
Funder:National Cancer Institute
Study End Date: 7/31/2022
KP Precision Medicine Assessment and ResponseInvestigators: Andrea Burnett-Hartman, PhD, MPH
The primary objective of this project is to identify attitudes, barriers, and facilitators to genetic testing and research participation among KP members.
Funder:Garfield Memorial Fund
Study End Date: 4/30/2019